培哚普利对充血性心力衰竭患者血清Fas/Apo-1水平的影响

Effect of perindopril on Fas/Apo-1 in patients with congestive heart failure

目的 :观察培哚普利对充血性心力衰竭 (CHF)患者细胞凋亡抑制因子Fas/Apo 1的影响 .方法 :酶联免疫方法检测 84例CHF患者 (培哚普利治疗 4 2例、常规治疗 4 2例 )治疗前、后及 30例健康人血清中Fas/Apo 1水平 .结果 :①与健康人相比 ,84例CHF患者Fas/Apo 1水平显著升高 [分别为(0 .10± 0 .0 4 ) μg·L-1和 (0 .2 0± 0 .0 7) μg·L-1,P <0 .0 1],CHF患者Fas/Apo 1水平随着心功能损害加重而升高 ,各组间有显著性差异 (P <0 .0 5 ) ;②培哚普利组与常规治疗组治疗前Fas/Apo 1水平两组间无显著差异 [分别为(0 .2 0± 0 .0 7)μg·L-1和 (0 .2 1± 0 .0 7) μg·L-1];与常规治疗组相比 ,培哚普利组治疗后血清中Fas/Apo 1降低更为明显 [分别为 (0 .12±0 .0 4 ) μg·L-1和 (0 .15± 0 .0 5 ) μg·L-1,P <0 .0 1].结论 :CHF患者血清中Fas/Apo 1水平可反映心力衰竭的严重程度 ,培哚普利改善CHF患者心脏功能的作用可能与其抑制心肌细胞的凋亡的机制有关 .

AIM: To observe the effect of perindopril on the cardiac function and serum level of Fas/Apo 1 in patients with congestive heart failure (CHF). METHODS: Level of serum Fas/Apo 1 was determined by enzyme linked immunosorbent assay (ELISA) in 84 CHF cases (42 treated with perindopril and 42 with conventional method) and 30 healthy cases as control. RESULTS: ① The level of Fas/Apo 1 in the 84 CHF cases was much higher than that in the control cases [(0.20±0.07) μg·L -1 vs (0.10±0.04) μg·L -1 , P <0.01] and increased significantly with the aggravation of cardiac dysfunction. ② Before treatment, there was no significant difference in serum level of Fas/Apo 1 between perindopril group and conventional group[(0.20±0.07) μg·L -1 vs (0.21±0.07) μg·L -1 ], but after treatment, the Fas/Apo 1 level in the perindopril group was significantly lower ( P <0.01) than that in conventional group [(0.12±0.04) μg·L -1 vs (0.15±0.05) μg·L -1 , P <0.01]. CONCLUSION: Level of circulating Fas/Apo 1 can be used to determine the cardiac dysfunction degree and perindopril may play an important role in protecting cardiac function by inhibiting the myocardium apoptosis process in patients with CHF.